Oxford Cannabinoid Technologies Holdings Plc (OCTP.L) LSE
0.12
-0.005(-4.17%)
Currency In GBp
- General
- Statistics
- Historical Data
- Profile
- Financials
Oxford Cannabinoid Technologies Holdings Plc
Address
Maddox House
London, W1S 2PZ
United Kingdom of Great Britain and Northern Ireland (the)
Phone
44 20 3034 2820
Website
Sector
Healthcare
Industry
Biotechnology
Employees
7
First IPO Date
May 21, 2021
Key Executives
| Name | Title | Pay | Year Born |
| Clarissa Ann Sowemimo-Coker | Chief Executive Officer & Executive Director | 215,669 | 1980 |
| Indraneil Mahapatra | Co-Founder & Non-Executive Director | 25,000 | 1980 |
| Paul William Smalley | Finance Director & Executive Director | 155,159 | 1973 |
| Timothy H. Corn | Executive Director & Chief Medical Officer | 0 | 1951 |
| Valentino Parravicini | Chief Scientific Officer | 0 | 1969 |
| Robin Bennett | General Counsel & Company Secretary | 0 | N/A |
Description
Oxford Cannabinoid Technologies Holdings Plc, a pharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based prescription medicines. Its lead drug candidate is OCT461201, a selective CB2 receptor agonist in solid oral dosage form that is in pre-clinical development for use in the treatment of IBS-associated visceral pain, as well as neuropathic pain conditions, including post herpetic neuralgia. The company is also developing OCT130401, which is in pre-clinical development for the treatment of trigeminal neuralgia. Oxford Cannabinoid Technologies Holdings Plc was incorporated in 2017 and is headquartered in London, the United Kingdom.
